Evolution of lesions over 10 years in a patient with SLE: flowchart approach to the new International Society of Nephrology (ISN)/Renal Pathology Society (RPS) classification of lupus nephritis

Am J Kidney Dis. 2006 Jan;47(1):184-90. doi: 10.1053/j.ajkd.2005.06.027.
No abstract available

Publication types

  • Case Reports
  • Clinical Conference

MeSH terms

  • Adolescent
  • Angiotensin II Type 1 Receptor Blockers / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Atorvastatin
  • Biopsy, Needle
  • Disease Progression
  • Follow-Up Studies
  • Hematuria / etiology
  • Heptanoic Acids / therapeutic use
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hyperlipidemias / drug therapy
  • Hyperlipidemias / etiology
  • Immunoglobulin A / analysis
  • Immunoglobulin M / analysis
  • Immunosuppressive Agents / therapeutic use
  • Kidney Glomerulus / ultrastructure*
  • Lupus Erythematosus, Systemic / complications
  • Lupus Erythematosus, Systemic / diagnosis
  • Lupus Erythematosus, Systemic / drug therapy
  • Lupus Nephritis / classification
  • Lupus Nephritis / drug therapy
  • Lupus Nephritis / pathology*
  • Lupus Nephritis / therapy
  • Male
  • Organelles / ultrastructure
  • Plasma Exchange
  • Pyrroles / therapeutic use
  • Sclerosis
  • Severity of Illness Index
  • Software Design

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors
  • Heptanoic Acids
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Immunoglobulin A
  • Immunoglobulin M
  • Immunosuppressive Agents
  • Pyrroles
  • Atorvastatin